Results 31 to 40 of about 785,080 (295)

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Grewia polysaccharide as a pharmaceutical excipient in matrix tablets [PDF]

, 2011
Matrix-based tablets using different concentrations of grewia gum, and the model drug ibuprofen, were prepared using a wet granulation technique. Similar formulations were also prepared using HPMC, guar gum or ethyl cellulose as the polymer matrix.
Conway, Barbara R, Barbara R. Conway, Nep, Elijah I., Nep, E.I., Conway, Barbara R., Elijah I. Nep   +5 more
core   +4 more sources

WHO Expert Committee on Specifications for Pharmaceutical Preparations [meeting held in Geneva from 4 to 9 November 1974] : twenty-fifth report [PDF]

, 1975
Russian version of nos. 563-585 bound together (barcode no.
World Health Organization, WHO Expert Committee on Specifications for Pharmaceutical Preparations. Meeting   +1 more
core  

L‐aspartate oxidase provides new insights into fumarate reduction in anaerobic darkness in Synechocystis sp. PCC6803

FEBS Letters, EarlyView.
Synechocystis strains deficient in succinate dehydrogenase (SDH) secrete more succinate than the WT under dark anaerobic conditions, supporting that SDH then primarily acts as SDH, not as a fumarate reductase. L‐aspartate oxidase (Laspo) from Synechocystis is functional under anaerobic conditions, reducing fumarate to succinate.
Kateryna Kukil, Jeffrey A. Hawkes, Cecilia Blikstad, Pia Lindberg   +3 more
wiley   +1 more source

Immunosuppressant adherence after heart transplantation: a review on detection, prevention, and intervention strategies in a multidisciplinary

Frontiers in Cardiovascular Medicine
Heart transplantation is an effective treatment for end-stage heart disease, and postoperative patients' medication adherence is crucial for transplantation outcomes and long-term survival.
Ziying Fan, Yong Han, Guojun Sun, Zuojun Dong   +3 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

Pedalitin could regulate lipid metabolism and attenuate inflammatory factors in a non-alcoholic fatty liver disease cell model

Journal of Holistic Integrative Pharmacy
Nonalcoholic fatty liver disease (NAFLD) is an escalating global health issue, leading to liver fat accumulation, inflammation, fibrosis, and potential liver failure.
Wanying He, Yaying Yu, Hui He, Qian Huang, Zhiting Liu, Fan Yang, Lin Zhou   +6 more
doaj   +1 more source

Nanomedicine potentiates mild photothermal therapy for tumor ablation

Asian Journal of Pharmaceutical Sciences, 2021
The booming photothermal therapy (PTT) has achieved great progress in non-invasive oncotherapy, and paves a novel way for clinical oncotherapy. Of note, mild temperature PTT (mPTT) of 42–45 °C could avoid treatment bottleneck of the traditional PTT ...
Zijun Jiang, Tianyi Li, Hao Cheng, Feng Zhang, Xiaoyu Yang, Shihao Wang, Jianping Zhou, Yang Ding   +7 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Inhaled nucleic acid delivery systems for the treatment of pulmonary interstitial diseases: Challenges and opportunities

Acta Pharmaceutica Sinica B
The treatment of interstitial lung diseases (ILDs) was important to reduce the inflammation or fibrosis within the interstitial space. In recent years, a variety of undruggable ILDs targets were emerged for anti-inflammation and anti-fibrosis therapy ...
Jingwen Dong, Jiahui Chen, Junmei Mu, Yinuo Fan, Jinsu Wang, Qiyan Zhang, Lin Zhang, Zhanwei Zhou, Minjie Sun   +8 more
doaj   +1 more source